Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA ® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITY TM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-’568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO , February 6, 2025 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided financial guidance for 2025. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA for patients living with tardive dyskinesia or Huntington disease chorea. With the approval and launch of CRENESSITY, we look forward to delivering the first new treatment for the congenital adrenal hyperplasia community in over 70 years, transforming the standard of care for patients,” said Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences. “With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company.” Financial Highlights Three Months Ended December 31, Twelve Months Ended December

later in the release …

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.